Kintor Pharma completes 52-week human safety trial of skin-whitening ingredient KT-939

• Kintor Pharmaceutical completed a 52-week long-term human safety trial of KT-939 on Sept. 4, 2026.
• Preliminary results have been presented; final results have not been scheduled for a future presentation.
• Trial outcome pointed to a clean safety profile, with no adverse skin reactions reported during continuous use.
• Data set supports an NMPA registration filing, a key step toward commercial launch in China’s cosmetics raw-material market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260907-12322374), on September 06, 2026, and is solely responsible for the information contained therein.